125 related articles for article (PubMed ID: 37996058)
1. SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer.
Gong DA; Zhou P; Chang WY; Yang JY; Zhang YL; Huang AL; Tang N; Wang K
Biochim Biophys Acta Mol Cell Res; 2024 Feb; 1871(2):119642. PubMed ID: 37996058
[TBL] [Abstract][Full Text] [Related]
2. Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by the generation of phosphatidylinositol 5-phosphate.
Bunce MW; Boronenkov IV; Anderson RA
J Biol Chem; 2008 Mar; 283(13):8678-86. PubMed ID: 18218622
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
4. Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.
Huang Y; Tan N; Jia D; Jing Y; Wang Q; Li Z; Zhang J; Liu L; Li J; Chen Z; He X
Tumour Biol; 2015 Dec; 36(12):9753-61. PubMed ID: 26156804
[TBL] [Abstract][Full Text] [Related]
5. CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET.
Wang S; Qiu J; Liu L; Su C; Qi L; Huang C; Chen X; Zhang Y; Ye Y; Ding Y; Liang L; Liao W
J Exp Clin Cancer Res; 2020 Aug; 39(1):168. PubMed ID: 32843066
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
7. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
8. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
[TBL] [Abstract][Full Text] [Related]
9. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.
Zhang P; Gao K; Jin X; Ma J; Peng J; Wumaier R; Tang Y; Zhang Y; An J; Yan Q; Dong Y; Huang H; Yu L; Wang C
Cell Death Dis; 2015 Mar; 6(3):e1687. PubMed ID: 25766326
[TBL] [Abstract][Full Text] [Related]
10. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of SPOP protein in tumorigenesis and cancer therapy.
Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
[TBL] [Abstract][Full Text] [Related]
12. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.
Ji P; Liang S; Li P; Xie C; Li J; Zhang K; Zheng X; Feng M; Li Q; Jiao H; Chi X; Zhao W; Zhang S; Wang X
Biochem Biophys Res Commun; 2018 Jul; 502(1):30-42. PubMed ID: 29777712
[TBL] [Abstract][Full Text] [Related]
13. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
14. Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
Bouchard JJ; Otero JH; Scott DC; Szulc E; Martin EW; Sabri N; Granata D; Marzahn MR; Lindorff-Larsen K; Salvatella X; Schulman BA; Mittag T
Mol Cell; 2018 Oct; 72(1):19-36.e8. PubMed ID: 30244836
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
16. Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles.
Marzahn MR; Marada S; Lee J; Nourse A; Kenrick S; Zhao H; Ben-Nissan G; Kolaitis RM; Peters JL; Pounds S; Errington WJ; Privé GG; Taylor JP; Sharon M; Schuck P; Ogden SK; Mittag T
EMBO J; 2016 Jun; 35(12):1254-75. PubMed ID: 27220849
[TBL] [Abstract][Full Text] [Related]
17. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
20. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression.
Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW
EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
